J
James Gajewski
Researcher at Oregon Health & Science University
Publications - 188
Citations - 15502
James Gajewski is an academic researcher from Oregon Health & Science University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 62, co-authored 187 publications receiving 14941 citations. Previous affiliations of James Gajewski include University of Texas MD Anderson Cancer Center & University of California, San Francisco.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.
Issa F. Khouri,Michael J. Keating,M. Korbling,Donna Przepiorka,Paolo Anderlini,Susan O'Brien,Sergio Giralt,Cindy Ippoliti,B. Von Wolff,James Gajewski,M. Donato,David F. Claxton,Naoto T. Ueno,Borje S. Andersson,Adrian P. Gee,Richard E. Champlin +15 more
TL;DR: The ability to induce remissions with donor lymphocyte infusion in patients with CLL, Richter's, and low-grade and intermediate-grade lymphoma is direct evidence of GVL activity against lymphoid malignancies.
Journal ArticleDOI
Analysis of 462 transplantations from unrelated donors facilitated by the national marrow donor program
Nancy A. Kernan,Glenn E. Bartsch,Robert C. Ash,Patrick G. Beatty,Richard E. Champlin,Alexandra H. Filipovich,James Gajewski,John A. Hansen,Jean P. Henslee-Downey,Jeffrey McCullough,Philip B. McGlave,Herbert A. Perkins,Gordon L. Phillips,Jean E. Sanders,David F. Stroncek,E. Donnall Thomas,Karl G. Blume +16 more
TL;DR: The National Marrow Donor Program has benefited a substantial number of patients in need of marrow transplants from closely HLA-matched unrelated donors and has facilitated the recruitment of unrelated donors into the donor pool and the access to suitable marrow.
Journal ArticleDOI
Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
Sergio Giralt,Peter F. Thall,Issa F. Khouri,Xuemei Wang,Ira Braunschweig,Cindy Ippolitti,David F. Claxton,Michele L. Donato,J. Bruton,A. Cohen,Marilyn S. Davis,Borje S. Andersson,Paolo Anderlini,James Gajewski,Steven M. Kornblau,Michael Andreeff,Donna Przepiorka,Naoto T. Ueno,Jeffrey J. Molldrem,Richard E. Champlin +19 more
TL;DR: Fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population, according to multivariate analysis.
Journal ArticleDOI
Results of Allogeneic Bone Marrow Transplants for Leukemia Using Donors Other Than HLA-Identical Siblings
Richard Szydlo,John M. Goldman,John P. Klein,Robert Peter Gale,Robert C. Ash,F. H. Bach,B.A. Bradley,James T. Casper,Neal Flomenberg,James Gajewski,Eliane Gluckman,P J Henslee-Downey,J M Hows,N Jacobsen,HJ Kolb,B. Lowenberg,Tohru Masaoka,Philip A. Rowlings,Paul M. Sondel,D. W. van Bekkum,J.J. van Rood,Marcus R. Vowels,Mei-Jie Zhang,Mary M. Horowitz +23 more
TL;DR: In early leukemia, alternative donor transplants have a more than twofold increased risk of treatment failure compared with HLA-identical sibling transplants, but this difference is less in advanced leukemia.